{"analyses":[{"ciLowerLimit":"1.19","ciNumSides":"TWO_SIDED","ciPctValue":"80","ciUpperLimit":"4.46","groupDescription":"To conclude success for the intervention, the Bayesian analysis must yield a minimum of 99% posterior probability for PFS Hazard ratio less than 1 \\[i.e., Pr(HR \\< 1) \\> 99%\\]. The Bayesian analyses below include posterior mean of Hazard ratio, posterior probabilities instead of p-values, and credible intervals instead of confidence intervals.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.051","paramType":"Posterior Mean Hazard Ratio","paramValue":"2.62","statisticalMethod":"Bayesian hierarchical model"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2","upperLimit":"6","value":"2.10"},{"comment":"There were not enough events to estimate the upper confidence limit.","groupId":"OG001","lowerLimit":"1.38","upperLimit":"NA","value":"2.03"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"description":"PFS is defined as the time from randomization until the first investigator-determined objective progression as defined by Response Evaluation Criteria In Solid Tumors, Version 1.1 (RECIST v1.1) or death from any cause in the absence of progressive disease. Participants known to be alive and without disease progression will be censored at the time of the last adequate tumor assessment or date of randomization, whichever is later.","dispersionType":"80% Confidence Interval","groups":[{"description":"Participants received intravenous infusions of ramucirumab 9 mg/kg, gemcitabine 900 mg/m2 on days 1, 8, and docetaxel 75 mg/m2 on day 8 of a 21-day cycle until disease progression or a criterion for discontinuation were met.","id":"OG000","title":"Ramucirumab + Gemcitabine + Docetaxel"},{"description":"Participants received intravenous infusions of gemcitabine 900 mg/m2 on days 1, 8, and docetaxel 75 mg/m2 on day 8 of a 21-day cycle until disease progression or a criterion for discontinuation were met.","id":"OG001","title":"Gemcitabine + Docetaxel"}],"paramType":"MEDIAN","populationDescription":"All randomized participants (including the censored participants). Number of participants censored in Ramucirumab + Gemcitabine + Docetaxel=4, Gemcitabine + Docetaxel=2.","reportingStatus":"POSTED","timeFrame":"Baseline to Objective Progression or Death Due to Any Cause (Up To 6.4 Months)","title":"Progression Free Survival (PFS)","type":"PRIMARY","unitOfMeasure":"Months"}